SG Americas Securities LLC Has $285,000 Stock Holdings in Viemed Healthcare, Inc. (NASDAQ:VMD)

SG Americas Securities LLC lifted its holdings in shares of Viemed Healthcare, Inc. (NASDAQ:VMD) by 193.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 35,579 shares of the company’s stock after buying an additional 23,442 shares during the period. SG Americas Securities LLC’s holdings in Viemed Healthcare were worth $285,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Barclays PLC lifted its holdings in Viemed Healthcare by 342.3% in the 3rd quarter. Barclays PLC now owns 53,439 shares of the company’s stock worth $392,000 after purchasing an additional 41,358 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Viemed Healthcare by 151.7% in the third quarter. JPMorgan Chase & Co. now owns 98,798 shares of the company’s stock worth $724,000 after buying an additional 59,538 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Viemed Healthcare by 748.2% during the 3rd quarter. Victory Capital Management Inc. now owns 108,497 shares of the company’s stock worth $795,000 after buying an additional 95,706 shares during the period. Wasatch Advisors LP grew its stake in Viemed Healthcare by 19.6% in the 3rd quarter. Wasatch Advisors LP now owns 1,848,884 shares of the company’s stock valued at $13,552,000 after buying an additional 303,277 shares during the last quarter. Finally, GSA Capital Partners LLP raised its holdings in Viemed Healthcare by 37.1% in the 3rd quarter. GSA Capital Partners LLP now owns 17,836 shares of the company’s stock worth $131,000 after acquiring an additional 4,829 shares during the period. Institutional investors and hedge funds own 74.24% of the company’s stock.

Viemed Healthcare Stock Up 2.2 %

Viemed Healthcare stock opened at $8.33 on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.31 and a quick ratio of 1.19. Viemed Healthcare, Inc. has a fifty-two week low of $6.21 and a fifty-two week high of $10.44. The firm has a fifty day moving average price of $8.29 and a two-hundred day moving average price of $8.08. The firm has a market cap of $324.37 million, a price-to-earnings ratio of 30.85 and a beta of 1.45.

Viemed Healthcare (NASDAQ:VMD) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.02. The business had revenue of $58.00 million during the quarter. Viemed Healthcare had a return on equity of 8.72% and a net margin of 4.87%.

Insiders Place Their Bets

In other Viemed Healthcare news, Director Nitin Kaushal sold 30,000 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $9.56, for a total value of $286,800.00. Following the sale, the director now directly owns 126,843 shares in the company, valued at $1,212,619.08. This trade represents a 19.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Randy E. Dobbs sold 36,261 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $9.28, for a total transaction of $336,502.08. Following the transaction, the director now owns 107,706 shares in the company, valued at approximately $999,511.68. The trade was a 25.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 72,256 shares of company stock valued at $674,739 in the last three months. Company insiders own 20.00% of the company’s stock.

Viemed Healthcare Company Profile

Viemed Healthcare, Inc, together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.